NeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 1.2 %

NASDAQ:NURO opened at $4.37 on Friday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The firm has a market capitalization of $9.00 million, a PE ratio of -0.95 and a beta of 1.82. The stock has a 50 day moving average of $4.40 and a 200-day moving average of $4.18.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. GTS Securities LLC acquired a new position in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned approximately 1.12% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is owned by institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.